Cathie Wood's Ark Invest Loads Up On Beam Therapeutics, Nu Holdings: Offloads MercadoLibre, Adaptive Biotechnologies
Ark Invest, through its ARK Fintech Innovation ETF ARKF -5.46% + Free Alerts , bought 162,143 shares of Nu Holdings Ltd. This marks a significant investment in the fintech company, reflecting Ark’s ...
FiercePharma2d
Pfizer discontinues hemophilia treatment Beqvez, emptying its gene therapy portfolio
Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez. | ...
Cathie Wood’s ARK Investment buys 171K shares of Beam Therapeutics today
EST Cathie Wood’s ARK Investment buys 171K shares of Beam Therapeutics (BEAM) todayDiscover the Best Stocks and Maximize Your Portfolio: ...
Morningstar3d
Beam Therapeutics Inc
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Cure Today8d
Understanding How One Must Interpret PSA Levels in Prostate Cancer
Dr. Barry W. Goy explains how to interpret PSA levels after prostate cancer treatment and how to manage recurrence based on ...
Targeted Oncology9d
Long-Term Outcomes of EBRT and Androgen Deprivation in Prostate Cancer
Barry Goy, MD, provides insight into the clinical implications of a retrospective analysis examining 15-year outcomes in patients with intermediate-risk prostate cancer.
The American Journal of Managed Care9d
Receiving NADT for 6 Months Doesn’t Impact Outcomes in Intermediate-Risk Prostate Cancer After EBRT
Adding 6 months of neoadjuvant deprivation therapy (NADT) doesn’t seem to add any benefit for patients with intermediate-risk ...